Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARN2966
- Development stage
- Preclinical
- Lead developer
- Aria Neurosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ARN2966 (also known as 2-PMAP) is a brain-penetrant, orally active small molecule that acts as a post-transcriptional modulator of amyloid precursor protein (APP) expression. It selectively inhibits the translation of APP mRNA without affecting its transcription levels, thereby reducing the steady-state levels of full-length APP and its downstream cleavage products, including amyloid-beta (Aβ) peptides (Aβ40 and Aβ42). Originally developed by New York University and Aria Neurosciences for the treatment of Alzheimer's disease, ARN2966 has also been investigated for its potential to block the App-Cd74 signaling axis, which drives macrophage pyroptosis and renal inflammation in autosomal dominant tubulointerstitial kidney disease due to UMOD mutations (ADTKD-UMOD).
- Other names
- 2-((pyridin-2-ylmethyl)amino)phenol2-PMAPPhenol, 2-[(2-pyridinylmethyl)amino]-
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on ARN2966.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARN2966.